Dementia

In this March 11, 2020, photo, Kalianthi Karipidu, 89, poses for a photo at the windows of her home in central Rome. Italy has one of the world’s oldest populations, and the coronavirus outbreak is taking its toll on family relationships. The elderly are sealing themselves off from loved ones or can’t be visited due to nursing home rules or travel restrictions. (AP Photo/Alessandra Tarantino)
March 12, 2020 - 6:20 am
ROME (AP) — Natalina De Santis’ three adult children come to her front door, bringing food to keep her healthy and books to relieve her boredom, but she doesn’t let them in any more. Widowed a few months ago and living alone, the 83-year-old resident of Rome is so afraid of catching the coronavirus...
Read More
February 07, 2020 - 12:37 pm
AMSTERDAM (AP) — A Dutch organization that carries out euthanasia received 3,122 requests last year, a 22% increase from the year before, the Euthanasia Expertise Center said Friday. “Every work day, 13 people say: 'Help me, I can’t go on,'” Steven Pleiter, director of the center formerly known as...
Read More
February 07, 2020 - 9:04 am
AMSTERDAM (AP) — A Dutch organization that carries out euthanasia received 3,122 requests last year, a 22% increase from the year before, the Euthanasia Expertise Center said Friday. “Every work day, 13 people say: 'Help me, I can’t go on,'” Steven Pleiter, director of the center formerly known as...
Read More
In this Nov. 22, 2019, photo, Charles Flagg, who is stricken with Alzheimer's disease, receives the contents of an intravenous bag while participating in a study on the drug Aducanumab at Butler Hospital in Providence, R.I. New results were released on the experimental medicine whose maker claims it can slow the decline of Alzheimer's disease, the most common form of dementia. (AP Photo/Charles Krupa)
December 05, 2019 - 3:20 pm
SAN DIEGO (AP) — A company that claims to have the first drug to slow mental decline from Alzheimer's disease made its case to scientists Thursday but left them sharply divided over whether there’s enough evidence of effectiveness for the medicine to warrant federal approval. Excitement and...
Read More
This undated photo provided by Acadia Pharmaceuticals Inc. shows a bottle of Nuplazid, a drug that was tested for treating psychosis related to dementia. If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer's in nearly two decades. Results from a study on the drug were disclosed Wednesday, Dec. 4, 2019, at an Alzheimer's conference in San Diego. (Acadia Pharmaceuticals Inc. via AP)
December 04, 2019 - 8:53 pm
SAN DIEGO (AP) — A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's disease and other forms of dementia in a study that was stopped early because the benefit seemed clear. If regulators agree, the drug could become the first treatment specifically for...
Read More
FILE - In this Nov. 6, 2015 file photo, an elderly couple walks down a hall in Easton, Pa. Research released on Friday, Nov. 1, 2019 suggests many American adults inaccurately estimate their chances for developing dementia and do useless things to prevent it. (AP Photo/Matt Rourke, File)
November 15, 2019 - 12:53 pm
Many older American adults may inaccurately estimate their chances for developing dementia and do useless things to prevent it, new research suggests. Almost half of adults surveyed believed they were likely to develop dementia. The results suggest many didn’t understand the connection between...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 6:44 pm
Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the drug company earlier this year stopped two...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 4:13 pm
Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the drug company earlier this year stopped two...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 10:40 am
The drug company Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the company earlier this year...
Read More
FILE - In this Oct. 11, 2019, file image taken with a slow shutter speed a soccer player runs for the ball during the Euro 2020 group A qualifying soccer match in Prague, Czech Republic. A study, from the University of Glasgow and reported Monday, Oct. 21, in New England Journal of Medicine, of former professional soccer players in Scotland found that they were less likely to die of common causes such as heart disease and cancer compared with the general population but more likely to die from dementia. (AP Photo/Petr David Josek, File)
October 21, 2019 - 12:53 pm
LONDON (AP) — A study of former professional soccer players in Scotland finds that they were less likely to die of common causes such as heart disease and cancer compared with the general population but more likely to die from dementia. The results raise fresh concerns about head-related risks from...
Read More

Pages